Entrectinib in NTRK fusion-positive (NTRK-fp) breast cancer: Updated data from STARTRK-2

被引：1
|
作者：
Lu, J. [1 ]
Blakely, C. M. [2 ]
Barve, M. [3 ]
Chung, C. H. [4 ]
Waqar, S. N. [5 ]
Hu, X. [6 ]
Delord, J-P. [7 ]
Krzakowski, M. J. [8 ]
Yonemori, K. [9 ]
Chen, D. T. [10 ]
Klingbiel, D. [11 ]
Heinzmann, S. [12 ]
Le Tourneau, C. [13 ]
机构：
[1] USC Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA USA
[2] Univ Calif San Francisco, Dept Med, Helen Diller Comprehens Canc Ctr, San Francisco, CA 94143 USA
[3] Mary Crowley Canc Res Ctr, Dallas, TX USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Dept Head & Neck Endocrine Oncol, Tampa, MD USA
[5] Washington Univ, Sch Med, Div Oncol, St Louis, MO USA
[6] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[7] Inst Univ Canc, Clin Res Unit, Toulouse, Haute Garonne, France
[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Lung Canc & Thorac Tumors, Warsaw, Poland
[9] Natl Canc Ctr, Dept Med Oncol, Tokyo, Japan
[10] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[11] F Hoffmann La Roche Ltd, Pharma Dev Data Sci, Data & Stat Sci, Basel, Switzerland
[12] F Hoffmann La Roche Ltd, Prod Dev & Med Affairs, Data & Stat Sci, Basel, Switzerland
[13] Paris Saclay Univ, Inst Curie, Dept Drug Dev & Innovat, Paris, France
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.192
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
173P
引用
收藏
页码：S204 / S205
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF LAROTRECTINIB AND ENTRECTINIB FOR ADULT PATIENTS WITH NTRK GENE FUSION-POSITIVE BREAST CANCER
    Dheer, P.
    Kamerikar, V
    Fleming, M.
    Seoane-Vazquez, E.
    VALUE IN HEALTH, 2024, 27 (06) : S110 - S110
  • [32] Entrectinib in NTRK-fusion positive gastrointestinal cancers: integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1, and ALKA-372-001)
    Siena, S.
    Demetri, G.
    Doebele, R.
    Chae, Y.
    Conkling, P.
    Garrido-Laguna, I.
    Garrido, P.
    Rolfo, C.
    Sigal, D.
    Eng, S.
    Simmons, B.
    Ye, C.
    Ciardiello, F.
    ANNALS OF ONCOLOGY, 2019, 30
  • [33] Efficacy and safety of entrectinib in an Asian population with NTRK fusion-positive (fp) solid tumours or ROS1-fp NSCLC
    Tan, D. S. W.
    Ahn, M-J.
    Chiu, C-H.
    Ohe, Y.
    Loong, H. H. F.
    Chee, C. E.
    Kim, S-W.
    Takeda, M.
    Li, Y-C.
    Cheng, A.
    Hida, T.
    Kim, D-W.
    Nogami, N.
    Su, W-C.
    Tanaka, H.
    Osborne, S.
    Freund, R.
    Chen, D.
    Seto, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S1358 - S1359
  • [34] Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/ metastatic NTRK fusion-positive (fp) non-small cell lung cancer (NSCLC)
    Cho, Byoung Chul
    Chiu, Chao-Hua
    Massarelli, Erminia
    Buchschacher, Gary L.
    Goto, Koichi
    Overbeck, Tobias R.
    Loong, Herbert H. F.
    Chee, Cheng E.
    Garrido, Pilar
    Heinzmann, Sebastian
    Bordogna, Walter
    Zeuner, Harald
    Osborne, Stuart
    John, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [35] Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
    Lu, S.
    Chiu, C-H.
    Yu, Y.
    Loong, H. H. F.
    Lin, C. C.
    Hu, X.
    Dong, X.
    Li, J.
    Zhao, J.
    Ye-Hui, S.
    Zhang, Z.
    Zhao, N.
    Xia, J.
    Wang, D.
    Fan, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S83 - S84
  • [36] Entrectinib in NTRK fusion-positive sarcoma: integrated analysis of patients enrolled in STATRK-2, STARTRK-1 and ALKA-372-001
    Wolf, J.
    Liu, S. V.
    Paz-Ares, L.
    Hu, J.
    Cho, B. C.
    Krzakowski, M.
    Chung, C. H.
    Patel, M.
    Taylor, M.
    Zeuner, H.
    Aziez, A.
    Huang, X.
    Osborne, S.
    Farago, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 34 - 34
  • [37] NTRK fusion-positive colorectal cancer in Japanese population
    Yonemaru, Junpei
    Hashimoto, Taiki
    Takayanagi, Daisuke
    Naka, Tomoaki
    Yatabe, Yasushi
    Kanemitsu, Yukihide
    Shiraishi, Kouya
    Sekine, Shigeki
    PATHOLOGY INTERNATIONAL, 2021, 71 (05) : 355 - 359
  • [38] COST-EFFECTIVENESS ANALYSIS OF ENTRECTINIB FOR TREATMENT NTRK FUSION-POSITIVE TUMORS IN CZECH REPUBLIC
    Dolezel, J.
    Pour, M.
    Motylova, S.
    Novak, J.
    Skalicky, D.
    VALUE IN HEALTH, 2022, 25 (12) : S101 - S101
  • [39] Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases
    John, T.
    Chiu, C-H.
    Cho, B. C.
    Fakih, M.
    Farago, A. F.
    Demetri, G. D.
    Goto, K.
    Doebele, R. C.
    Siena, S.
    Drilon, A.
    Patel, M. R.
    Liu, S. V.
    Ahn, M-J.
    Bazhenova, L.
    Overbeck, T. R.
    Nieva, J.
    Kim, S-W.
    Veronese, L.
    Day, B-M.
    De Braud, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S397 - S398
  • [40] Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
    Paz-Ares, L.
    Dziadziuszko, R.
    Drilon, A.
    John, T.
    Krebs, M.
    Demetri, G.
    Shaw, A.
    Siena, S.
    Wolf, J.
    Farago, A.
    Simmons, B.
    Ye, C.
    Huang, X.
    Doebele, R.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S305 - S305
12345